ID: ALA536967

Max Phase: Preclinical

Molecular Formula: C24H27ClN4O4S

Molecular Weight: 466.56

Molecule Type: Small molecule

Representations

Canonical SMILES:  Cc1ccc(NCS(=O)(=O)c2ccccc2)c(O)c1CC(=O)NCc1ccc(C(=N)N)cc1.Cl

Standard InChI:  InChI=1S/C24H26N4O4S.ClH/c1-16-7-12-21(28-15-33(31,32)19-5-3-2-4-6-19)23(30)20(16)13-22(29)27-14-17-8-10-18(11-9-17)24(25)26;/h2-12,28,30H,13-15H2,1H3,(H3,25,26)(H,27,29);1H

Standard InChI Key:  PBEKRIQGBBNTDR-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 466.56

Molecular Weight (Monoisotopic): 466.1675

AlogP: 2.69

#Rotatable Bonds: 9

Polar Surface Area: 145.37

Molecular Species: BASE

HBA: 6

HBD: 5

#RO5 Violations: 0

HBA (Lipinski): 8

HBD (Lipinski): 6

#RO5 Violations (Lipinski): 1

CX Acidic pKa: 10.04

CX Basic pKa: 11.50

CX LogP: 1.59

CX LogD: -0.21

Aromatic Rings: 3

Heavy Atoms: 33

QED Weighted: 0.19

Np Likeness Score: -0.98

References

1. Hanessian S, Therrien E, van Otterlo WA, Bayrakdarian M, Nilsson I, Fjellström O, Xue Y..  (2006)  Phenolic P2/P3 core motif as thrombin inhibitors--design, synthesis, and X-ray co-crystal structure.,  16  (4): [PMID:16290930] [10.1016/j.bmcl.2005.10.082]

Source

Source(1):

• Scientific Literature